Literature DB >> 12411658

Prevalence of atrial fibrillation and antithrombotic prophylaxis in emergency department patients.

Phillip A Scott1, Arthur M Pancioli, Lisa A Davis, Shirley M Frederiksen, John Eckman.   

Abstract

BACKGROUND AND
PURPOSE: The emergency department (ED), as the point of first medical contact for many complaints referable to atrial fibrillation (AF) and a common source of primary care, occupies a unique position to identify AF patients at risk of stroke. This study evaluates that potential by determining the prevalence of AF in an ED population and assessing antithrombotic use in those patients with recurrent AF.
METHODS: This was a multicenter, retrospective, cross-sectional study of consecutive records of ED patients with AF identified by ECG between January and June 1998. American Heart Association and modified Stroke Prevention in Atrial Fibrillation criteria established high-risk patients and contraindications to anticoagulation, respectively.
RESULTS: We identified 866 records with ECG-proven AF in 78 787 patient visits for an estimated prevalence of 1.10% (95% CI, 1.03 to 1.17). We found that 556 records had a prior history of AF; of these, 221 (40%) used warfarin alone, 155 (28%) had antiplatelet therapy alone, 28 (5%) used both, and 152 (27%) had no antithrombotic therapy identified. Sixty-eight patients (12%; 95% CI, 0.10 to 0.15) were warfarin eligible and without antithrombotic therapy. An additional 64 (12%; 95% CI, 0.09 to 0.14) had antiplatelet therapy alone. In warfarin-eligible patients, no differences were identified between the anticoagulated and nonanticoagulated groups on the basis of age, sex, or race. Of patients on warfarin with a measured international normalized ratio, 61% (95% CI, 0.55 to 0.67) were outside the AHA-recommended range of 2.0 to 3.0.
CONCLUSIONS: AF is a common finding in an ED population. Many are warfarin eligible and untreated or undertreated. Methods to increase anticoagulant use in this at-risk population warrant further investigation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12411658     DOI: 10.1161/01.str.0000035260.70403.88

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  16 in total

1.  A clinical prediction model to estimate risk for 30-day adverse events in emergency department patients with symptomatic atrial fibrillation.

Authors:  Tyler W Barrett; Amy R Martin; Alan B Storrow; Cathy A Jenkins; Frank E Harrell; Stephan Russ; Dan M Roden; Dawood Darbar
Journal:  Ann Emerg Med       Date:  2010-08-21       Impact factor: 5.721

2.  What are the barriers to warfarin use in atrial fibrillation?: Development of a questionnaire.

Authors:  Anders Ingelgård; Jennifer Hollowell; Prabashni Reddy; Karen Gold; Kimbach Tran; David Fitzmaurice
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

Review 3.  Global epidemiology of atrial fibrillation.

Authors:  Faisal Rahman; Gene F Kwan; Emelia J Benjamin
Journal:  Nat Rev Cardiol       Date:  2014-08-12       Impact factor: 32.419

4.  Misuse of antithrombotic therapy in atrial fibrillation patients: frequent, pervasive and persistent.

Authors:  Luciana S Fornari; Daniela Calderaro; Ivana B Nassar; Cristiane Lauretti; Lidia Nakamura; Renato Bagnatori; Walter Ageno; Bruno Caramelli
Journal:  J Thromb Thrombolysis       Date:  2007-02       Impact factor: 2.300

5.  Atrial fibrillation and flutter outcomes and risk determination (AFFORD): design and rationale.

Authors:  Tyler W Barrett; Alan B Storrow; Cathy A Jenkins; Frank E Harrell; Karen F Miller; Kelly M Moser; Stephan Russ; Dan M Roden; Dawood Darbar
Journal:  J Cardiol       Date:  2011-08-04       Impact factor: 3.159

6.  Stroke Prophylaxis for Atrial Fibrillation? To Prescribe or Not to Prescribe-A Qualitative Study on the Decisionmaking Process of Emergency Department Providers.

Authors:  Bory Kea; Tahroma Alligood; Cassandra Robinson; Josephine Livingston; Benjamin C Sun
Journal:  Ann Emerg Med       Date:  2019-05-09       Impact factor: 5.721

7.  Self-management of oral anticoagulation in nonvalvular atrial fibrillation (SMAAF study).

Authors:  H Völler; J Glatz; U Taborski; A Bernardo; C Dovifat; K Heidinger
Journal:  Z Kardiol       Date:  2005-03

8.  Structure and markers of appropriateness, quality and performance of drug treatment over a 1-year period after hospital discharge in a cohort of elderly patients with cardiovascular diseases from Germany.

Authors:  Sebastian Harder; Philipp Fischer; Markus Krause-Schäfer; Klaus Ostermann; Gottfried Helms; Helge Prinz; Mike Hahmann; Horst Baas
Journal:  Eur J Clin Pharmacol       Date:  2004-12-01       Impact factor: 2.953

9.  Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study.

Authors:  Dominique Deplanque; Didier Leys; Lucilla Parnetti; Reinhold Schmidt; Jose Ferro; Jacques De Reuck; Jean-Louis Mas; Virgilio Gallai
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

10.  An emergency department intervention to increase warfarin use for atrial fibrillation.

Authors:  Lesli E Skolarus; Lewis B Morgenstern; Phillip A Scott; Lynda D Lisabeth; Jillian B Murphy; Erin M Migda; Devin L Brown
Journal:  J Stroke Cerebrovasc Dis       Date:  2012-12-21       Impact factor: 2.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.